Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Newly Identified Biomarkers to Pave Way for SIDS Screening Test

By LabMedica International staff writers
Posted on 13 Sep 2024

Approximately 1,300 infants under the age of one die each year from sudden infant death syndrome (SIDS), and researchers still do not fully understand the causes of these unexpected deaths. More...

It is known that multiple factors are likely contributors, including inadequate prenatal care, maternal smoking and alcohol use during pregnancy, structural racism, and air pollution. Male infants have a higher incidence of SIDS compared to females. Scientists are now turning to biological factors in the search for a cause of SIDS that could be identified at birth or targeted with medication. In a new study, researchers have identified signals within the metabolic systems of infants who died from SIDS and believe these metabolic indicators could be key in reducing mortality. While more research is needed, this discovery could one day help prevent SIDS.

In the study, investigators at UC San Francisco (San Francisco, CA, USA) drew on previous research suggesting that the metabolic system—which involves how bodies process and store energy—might play a role in SIDS. They decided to examine this system more closely by comparing metabolic data from infants collected during routine newborn screenings in California. They contrasted the data of infants who eventually died from SIDS with that of similar infants who survived. Among the 354 infants who died from SIDS, they found certain metabolic biomarkers that may be associated with an increased risk. For example, infants with lower levels of C-3 and higher levels of C-14OH appeared to have a greater risk of dying from SIDS. These findings, published in JAMA Pediatrics, are consistent with previous research linking enzymes involved in fatty acid oxidation to SIDS. The scientists also discovered several other biomarkers that, when elevated, seemed to correlate with a reduced risk of SIDS.

The research remains preliminary, and the scientists emphasized the need for validation in additional settings. While this study was conducted using records of infants who had already passed away, the authors noted that it would be ideal to study living infants and follow them as they develop. Although the ultimate goal of creating a screening test for SIDS is still distant, this development indicates the potential for future breakthroughs in preventing this devastating syndrome. The research team plans to next explore other metabolic markers and their genetic counterparts to see if they can identify even more factors contributing to SIDS.

"This study suggests that metabolic factors may play a crucial role in SIDS,” said Scott Oltman, MS, an epidemiologist at UCSF and first author of the study. “These patterns could help identify children at higher risk, potentially saving lives in the future. This study is a critical step toward integrating metabolic markers with potential genetic markers and other risk factors to better assess the risk of SIDS in infants."

Related Links:
UC San Francisco


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.